Clinical Trial

A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors

Enrolling by Invitation Phase 1/2
View on ClinicalTrials.gov →
Summary
A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-02-20; most recent amendment 2026-01-13.
Trial Details
NCT Number NCT05741242
Lead Sponsor Jaime Leandro Foundation for Therapeutic Cancer Vaccines
Conditions Cancer, Solid Tumor
Enrollment 136 participants
Start Date 2022-11-30
Primary Completion 2027-01 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-15